LSX are known for bringing life science investors together to assess and meet with the most promising up-and-coming biotech companies. When the first mRNA vaccines hit the market in 2020, one of our investors asked us to look at the resurgence of therapeutics targeting or made of RNA with the view to developing a high-level conference. And so, RNA Leaders was born.
The 2022 RNA Leaders Series saw 100+ world-class speakers and over 600+ senior leaders from around the world join the most comprehensive and only RNA industry-focused events in Europe (Basel) in the spring and the US (Boston) in the fall.
The community came together to hear the latest advances in RNA chemistry, get clinical updates from the companies developing new therapies, source the services partners who are helping to deliver drugs to patients and develop their network with over 750+ partnering meetings!
The explosion of the RNA field continues, and RNA medicines are at a critical moment in time. At first in wake of the pandemic mRNA vaccines dominated the headlines, although this is still the case mRNA therapeutics and vaccines to treat other infectious diseases and therapeutics like cancer are also taking centre stage.
Huge advances are also being made in RNAi and antisense technologies as our understanding of the chemistry evolves and AI platform progress discovery. Delivery tools are increasingly sophisticated and impactful. Advances in genomics and gene editing are driving new approaches. And exciting work targeting RNA with small molecules and non-linear RNAs are emerging.
With that in mind, we can鈥檛 wait to bring the community together, face-to-face, in spring 2024 for the third annual RNA Leaders Europe Congress.
And in the words of Moderna鈥檚 CSO, Melissa Moore:
鈥淲hen I saw some other speakers who had been invited, I felt this would be a really great place to connect with and network with my peers.鈥�
So, if you鈥檙e passionate about all things RNA please join biotech, pharmaceutical, investment, regulatory and scientific professionals at RNA Leaders Europe.
The 2022 RNA Leaders Series saw 100+ world-class speakers and over 600+ senior leaders from around the world join the most comprehensive and only RNA industry-focused events in Europe (Basel) in the spring and the US (Boston) in the fall.
The community came together to hear the latest advances in RNA chemistry, get clinical updates from the companies developing new therapies, source the services partners who are helping to deliver drugs to patients and develop their network with over 750+ partnering meetings!
The explosion of the RNA field continues, and RNA medicines are at a critical moment in time. At first in wake of the pandemic mRNA vaccines dominated the headlines, although this is still the case mRNA therapeutics and vaccines to treat other infectious diseases and therapeutics like cancer are also taking centre stage.
Huge advances are also being made in RNAi and antisense technologies as our understanding of the chemistry evolves and AI platform progress discovery. Delivery tools are increasingly sophisticated and impactful. Advances in genomics and gene editing are driving new approaches. And exciting work targeting RNA with small molecules and non-linear RNAs are emerging.
With that in mind, we can鈥檛 wait to bring the community together, face-to-face, in spring 2024 for the third annual RNA Leaders Europe Congress.
And in the words of Moderna鈥檚 CSO, Melissa Moore:
鈥淲hen I saw some other speakers who had been invited, I felt this would be a really great place to connect with and network with my peers.鈥�
So, if you鈥檙e passionate about all things RNA please join biotech, pharmaceutical, investment, regulatory and scientific professionals at RNA Leaders Europe.
